Using a computer-generated sequence , we randomly allocated eligible patients-those aged 18-55 years with relapsing-remitting multiple sclerosis-to receive fingolimod 05 mg , fingolimod 125 mg , or placebo orally once daily ( 1:1:1 ; stratified by study centre ) .